Mutations in the SNCA gene, which encodes α-synuclein (α-syn), play a key role in the development of genetic Parkinson’s disease (PD). α-Syn is a major component of Lewy bodies in PD and glial cytoplasmic inclusions in multiple system atrophy (MSA). Rapid eye movement sleep behavior disorder patients often progress to PD, dementia with Lewy bodies, or MSA, which are collectively known as α-synucleinopathies. The loss of dopaminergic neurons with Lewy bodies precedes motor dysfunction in these diseases, but the mechanisms of neurodegeneration due to α-syn aggregation are poorly understood. Monitoring α-syn aggregation in vivo could serve as a diagnostic biomarker and help elucidate pathogenesis, necessitating a simple and accurate detection method. Seed amplification assays (SAAs), such as real-time quaking-induced conversion and protein misfolding cyclic amplification, are used to detect small amounts of abnormally structured α-syn protofibrils, which are central to aggregation. These methods are promising for the early diagnosis of α-synucleinopathy. Differences in α-syn filament structures between α-synucleinopathies, as observed through transmission electron microscopy and cryo-electron microscopy, suggest their role in the pathogenesis of neurodegeneration. SAAs may differentiate between subtypes of α-synucleinopathy and other diseases. Efforts are also being made to identify α-syn from blood using various methods. This review introduces body fluid α-syn biomarkers based on pathogenic α-syn seeds, which are expected to redefine α-synucleinopathy diagnosis and staging, improving clinical research accuracy and facilitating biomarker development.
Citations
Citations to this article as recorded by
Selective detection of alpha synuclein amyloid fibrils by faradaic and non-faradaic electrochemical impedance spectroscopic approaches Hussaini Adam, Subash C.B. Gopinath, Hemavathi Krishnan, Tijjani Adam, Makram A. Fakhri, Evan T. Salim, A. Shamsher, Sreeramanan Subramaniam, Yeng Chen Bioelectrochemistry.2025; 161: 108800. CrossRef
Hypoxia Pathways in Parkinson’s Disease: From Pathogenesis to Therapeutic Targets Yuanyuan Gao, Jiarui Zhang, Tuoxian Tang, Zhenjiang Liu International Journal of Molecular Sciences.2024; 25(19): 10484. CrossRef
Circadian rhythm disruption: a potential trigger in Parkinson’s disease pathogenesis Ke Xu, Yu Zhang, Yue Shi, Yake Zhang, Chengguang Zhang, Tianjiao Wang, Peizhu Lv, Yan Bai, Shun Wang Frontiers in Cellular Neuroscience.2024;[Epub] CrossRef
Intracellular α-synuclein (α-syn) inclusions are a neuropathological hallmark of Lewy body disease (LBD) and multiple system atrophy (MSA), both of which are termed synucleinopathies. LBD is defined by Lewy bodies and Lewy neurites in neurons, while MSA displays glial cytoplasmic inclusions in oligodendrocytes. Pathological α-syn adopts an ordered filamentous structure with a 5–10 nm filament diameter, and this conformational change has been suggested to be involved in the disease onset and progression. Synucleinopathies also exhibit characteristic ultrastructural and biochemical properties of α-syn filaments, and α-syn strains with distinct conformations have been identified. Numerous experimental studies have supported the idea that pathological α-syn self-amplifies and spreads throughout the brain, during which processes the conformation of α-syn filaments may drive the disease specificity. In this review, we summarize the ultrastructural features and heterogeneity of α-syn filaments in the brains of patients with synucleinopathy and in experimental models of seeded α-syn aggregation.
Citations
Citations to this article as recorded by
α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders Taku Hatano, Ayami Okuzumi, Gen Matsumoto, Taiji Tsunemi, Nobutaka Hattori Journal of Movement Disorders.2024; 17(2): 127. CrossRef
Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein—An In Silico and Experimental Approach to Parkinson’s Disease Sophia A. Frantzeskos, Mary A. Biggs, Ipsita A. Banerjee Biomimetics.2024; 9(11): 705. CrossRef
This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.
Citations
Citations to this article as recorded by
A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism Kazuya Kawabata, Florian Krismer, Beatrice Heim, Anna Hussl, Christoph Mueller, Christoph Scherfler, Elke R. Gizewski, Klaus Seppi, Werner Poewe Movement Disorders Clinical Practice.2024; 11(4): 381. CrossRef
The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Arjun Ahluwalia, Andrew Awuah Wireko, Tomas Ferreira, Joecelyn Kirani Tan, Maximillian Wolfson, Shankhaneel Ghosh, Viktoriia Horbas, Vandana Garg, Asma Perveen, Marios Papadakis, Ghulam Md Ashraf, Ath CNS Neuroscience & Therapeutics.2024;[Epub] CrossRef
Delivering the diagnosis of multiple system atrophy: a multicenter survey on Japanese neurologists’ perspectives Miki Yoshitake, Atsuhiko Sugiyama, Takayoshi Shimohata, Nobuyuki Araki, Masahide Suzuki, Kazumoto Shibuya, Kengo Nagashima, Nobutaka Hattori, Satoshi Kuwabara BMC Neurology.2024;[Epub] CrossRef
Clinical comparison of the 2008 and 2022 diagnostic criteria for early multiple system atrophy-cerebellar type Seoyeon Kim, Kyung Ah Woo, Jung Hwan Shin, Han-Joon Kim, Beomseok Jeon Clinical Autonomic Research.2024; 34(6): 609. CrossRef
Ocular Vestibular-Evoked Myogenic Potential Assists in the Differentiation of Multiple System Atrophy From Parkinson’s Disease Keun-Tae Kim, Kyoungwon Baik, Sun-Uk Lee, Euyhyun Park, Chan-Nyoung Lee, Tonghoon Woo, Yukang Kim, Seoui Kwag, Hyunsoh Park, Ji-Soo Kim Journal of Movement Disorders.2024; 17(4): 398. CrossRef
The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.
Citations
Citations to this article as recorded by
The Role of Electroconvulsive Therapy in the Treatment of Catatonia Associated With Lewy Body Dementia: A Case Report Javeria Sahib Din, Thomas Boes, Ernesto Navarro Garcia, Hiba Al-Rubaye Cureus.2024;[Epub] CrossRef
α-Synuclein pathology from the body to the brain: so many seeds so close to the central soil Yunying Yang, Zhentao Zhang Neural Regeneration Research.2024; 19(7): 1463. CrossRef
Suspecting Non-Alzheimer’s Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images Vincent Malotaux, Lise Colmant, Lisa Quenon, Lara Huyghe, Thomas Gérard, Laurence Dricot, Adrian Ivanoiu, Renaud Lhommel, Bernard Hanseeuw Journal of Alzheimer's Disease.2024; 97(1): 421. CrossRef
Supercomplex formation of mitochondrial respiratory chain complexes in leukocytes from patients with neurodegenerative diseases Tsukasa Hara, Ryosuke Amagai, Ryuji Sakakibara, Ayako Okado-Matsumoto The Journal of Biochemistry.2024; 175(3): 289. CrossRef
Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with Lewy Bodies Mariane Vicente, Kwaku Addo-Osafo, Keith Vossel Frontiers in Neurology.2024;[Epub] CrossRef
The clinical diagnosis of Parkinson's disease Renato P. Munhoz, Vitor Tumas, José Luiz Pedroso, Laura Silveira-Moriyama Arquivos de Neuro-Psiquiatria.2024; 82(06): 001. CrossRef
Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach Megha Manoj, Siddarth Sowmyanarayan, Arjun V. Kowshik, Jhinuk Chatterjee Journal of Molecular Neuroscience.2024;[Epub] CrossRef
Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies Neha Atulkumar Singh, Austin W. Goodrich, Jonathan Graff-Radford, Mary M. Machulda, Irene Sintini, Arenn F. Carlos, Carling G. Robinson, Robert I. Reid, Val J. Lowe, Clifford R. Jack, Ronald C. Petersen, Bradley F. Boeve, Keith A. Josephs, Kejal Kantarci, NeuroImage.2024; 290: 120564. CrossRef
Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort Niyatee Samudra, D. Luke Fischer, Steven Lenio, Argentina Lario Lago, Peter A. Ljubenkov, Julio C. Rojas, William W. Seeley, Salvatore Spina, Adam M. Staffaroni, Jonathan Tablante, Fattin Wekselman, Jennifer Lamoureux, Luis Concha‐Marambio, Lea T. Grinber Alzheimer's & Dementia.2024; 20(5): 3334. CrossRef
New insight of exercise on dementia; combinatory effects of physical and cognitive exercise Hyo-Jeong Cha, Jun Hong Park, Changwan Hong Molecular & Cellular Toxicology.2024; 20(4): 767. CrossRef
Diagnostic Challenge of an Advanced Stage Dementia Case Emin Taşkıran European Journal of Geriatrics and Gerontology.2024; 6(1): 73. CrossRef
Dementia with Lewy bodies Cheri M. Jrolf JAAPA.2024;[Epub] CrossRef
Absolute quantitation of sympathetic nerve activity using [123I] metaiodobenzylguanidine SPECT-CT in neurology Shintaro Saito, Kenichi Nakajima, Junji Komatsu, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroshi Mori, Aki Takata, Kenjiro Ono, Seigo Kinuya EJNMMI Reports.2024;[Epub] CrossRef
Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging Kenichi Nakajima, Takeshi Matsumura, Junji Komatsu, Hiroshi Wakabayashi, Kenjiro Ono, Seigo Kinuya Annals of Nuclear Medicine.2024; 38(10): 814. CrossRef
The usefulness of combined analysis using CIScore and VSRAD parameters for differentiating between dementia with Lewy body and Alzheimer’s disease Gaku Honda, Shigeki Nagamachi, Mai Takahashi, Yukie Higuma, Tomonobu Tani, Kosuke Hida, Kengo Yoshimitsu, Koji Ogomori, Yoshio Tsuboi Japanese Journal of Radiology.2024; 42(10): 1206. CrossRef
Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies Annika Kluge, Alex Iranzo, Daniela Berg, Bastiaan R. Bloem, Lorraine V. Kalia, Ron B. Postuma Journal of Parkinson's Disease.2024; 14(s2): S323. CrossRef
Multiple system atrophy: Diagnostic challenges and a proposed diagnostic algorithm Deepmala Nandanwar, Daniel D. Truong Clinical Parkinsonism & Related Disorders.2024; 11: 100271. CrossRef
Substantia nigra hyperechogenicity and brain ventricular size as biomarkers of early dementia with Lewy bodies Anna Planas-Ballvé, Jose Rios, Mireia Gea, Neus Rabaneda-Lombarte, Lourdes Ispierto, Laia Grau, Marta Jiménez, Cynthia Cáceres, Sílvia Martínez, Katrin Beyer, Ramiro Álvarez, Pau Pastor, Dolores Vilas Alzheimer's Research & Therapy.2024;[Epub] CrossRef
The Diagnostic Challenges of Late-onset Neuropsychiatric Symptoms and Early-onset Dementia: A Clinical and Neuropathological Case Study Miguel Restrepo-Martinez, Ramiro Ruiz-Garcia, Jacob Houpt, Lee Cyn Ang, Sumit Chaudhari, Elizabeth Finger Cognitive and Behavioral Neurology.2024; 37(4): 226. CrossRef
Quantitative proteomic analysis using a mouse model of Lewy body dementia induced by α-synuclein preformed fibrils injection Fatih Akkentli, In kyu Jang, Yoonseop Choi, Young Min, Jinhee Park, Heejin Jo, Leoni Kim, Aashi Mendpara, Bikram Bains, Dongyoon Yoo, Jinchong Xu, Chan Hyun Na, Sung-Ung Kang Frontiers in Dementia.2024;[Epub] CrossRef
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes Alexandros Giannakis, Chrissa Sioka, Eugenia Kloufetou, Spiridon Konitsiotis Journal of Neural Transmission.2024;[Epub] CrossRef
Magnetic resonance imaging in the diagnosis of progressive supranuclear palsy: A case report and review of literature Baraka Alphonce, Francisca Komanya, Mbelwa Bitesigilwe, John R. Meda, Azan Nyundo Clinical Case Reports.2023;[Epub] CrossRef
Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes Jun Yang, Ayotimofe Idowu, Liana Rosenthal, Xiaobo Mao Clinical and Translational Discovery.2023;[Epub] CrossRef
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia Irene Frigerio, Max A. Laansma, Chen-Pei Lin, Emma J. M. Hermans, Maud M. A. Bouwman, John G. J. M. Bol, Yvon Galis-de Graaf, Dagmar H. Hepp, Annemieke J. M. Rozemuller, Frederik Barkhof, Wilma D. J. van de Berg, Laura E. Jonkman Translational Neurodegeneration.2023;[Epub] CrossRef
Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Michael Ljungberg, Tetsuo Hosoya, Yumiko Kirihara, Mitsumasa Hashimoto Journal of Nuclear Cardiology.2023; 30(4): 1630. CrossRef
Costs During the Last Five Years of Life for Patients with Clinical and Pathological Confirmed Diagnosis of Lewy Body Dementia and Alzheimer’s Disease Carolyn W. Zhu, Yian Gu, Anton J. Kociolek, Kayri K. Fernandez, Stephanie Cosentino, Yaakov Stern Journal of Alzheimer's Disease.2023; 92(2): 457. CrossRef
Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study Li Zhou, Bei Huang, Jing Wang, Steven WH. Chau, Joey WY. Chan, Jihui Zhang, Mandy WM. Yu, Jessie CC. Tsang, Shirley Xin Li, Vincent CT. Mok, Yun Kwok Wing, Yaping Liu Sleep Medicine.2023;[Epub] CrossRef
Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions Oliver Phillips, Debolina Ghosh, Hubert H. Fernandez Current Treatment Options in Neurology.2023; 25(5): 93. CrossRef
Rapidly progressive dementia with severe insomnia: an unusual case of progressive supranuclear palsy mimicking dementia with Lewy bodies Rae On Kim, Eun Ji Lee, Seong-Ik Kim, Sung-Hye Park, Kyum-Yil Kwon Neurological Sciences.2023; 44(8): 2953. CrossRef
Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes Nils Schröter, Thilo van Eimeren, Joseph Classen, Johannes Levin, Christoph Redecker, Martin Wolz, Lars Tönges Journal of Neural Transmission.2023; 130(6): 839. CrossRef
Electroencephalography in young onset dementia Casey W Brown, Huei-Yang Chen, Peter K Panegyres BMC Neurology.2023;[Epub] CrossRef
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers Lucy L. Gibson, Carla Abdelnour, Joyce Chong, Clive Ballard, Dag Aarsland Current Opinion in Neurology.2023;[Epub] CrossRef
Coexistence of Posterior Cortical Atrophy and Parkinson’s Disease Eun-Byul Ko, Il-Joong Hwang, Jung-Woo Kim, Dar-Eun Jung, Ju-Suk Lee, Sang-Won Yoo, Joong-Seok Kim Journal of the Korean Neurological Association.2023; 41(3): 216. CrossRef
Toward a new nosology of neurodegenerative diseases Manuel Menéndez‐González Alzheimer's & Dementia.2023; 19(8): 3731. CrossRef
Autonomic dysfunction in dementia with Lewy bodies: Focusing on cardiovascular and respiratory dysfunction Katsuyoshi Mizukami Psychiatry and Clinical Neurosciences Reports.2023;[Epub] CrossRef
Beyond Strains: Molecular Diversity in Alpha-Synuclein at the Center of Disease Heterogeneity Marcelina J. Wojewska, Maria Otero-Jimenez, Jose Guijarro-Nuez, Javier Alegre-Abarrategui International Journal of Molecular Sciences.2023; 24(17): 13199. CrossRef
Case Study 6: The Diagnostic Challenge of a 75-Year-Old Man Who Had, Then Didn’t Have, Then Did Have Alzheimer’s Disease Sergio A. Ramírez-Salazar, Cassie MacRae, Mel B. Feany, Michael Miller, Hyun-Sik Yang, Mary-Ellen Meadows, Scott M. McGinnis, David Silbersweig, Seth A. Gale, Kirk R. Daffner The Journal of Neuropsychiatry and Clinical Neurosciences.2023; 35(4): 325. CrossRef
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review Jamir Pitton Rissardo, Ana Letícia Fornari Caprara Brain Sciences.2023; 13(10): 1471. CrossRef
A Unique Perspective on Lead Compounds for Dementia with the Lewy
Body Menaka Subramani, Amuthalakshmi Sivaperuman, Ramalakshmi Natarajan, Keerthana Dhinakaran Medicinal Chemistry.2023; 19(10): 946. CrossRef
Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac 123I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT Shintaro Saito, Kenichi Nakajima, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroto Yoneyama, Takahiro Konishi, Hiroshi Mori, Aki Takata, Seigo Kinuya Annals of Nuclear Cardiology.2023; 9(1): 61. CrossRef
Comparison of Taiwanese and European Calibration Factors for Heart-to-Mediastinum Ratio in Multicenter 123I-mIBG Phantom Studies Koichi Okuda, Kenichi Nakajima, Guang-Uei Hung, Hao-Ting Wu, Derk O. Verschure, Hein J. Verberne, Chiemi Kitamura Annals of Nuclear Cardiology.2023; 9(1): 54. CrossRef
Clinical biomarkers for Lewy body diseases Mai M. Abdelmoaty, Eugene Lu, Rana Kadry, Emma G. Foster, Shaurav Bhattarai, R. Lee Mosley, Howard E. Gendelman Cell & Bioscience.2023;[Epub] CrossRef
Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia Yael Hirschberg, Natalia Valle‐Tamayo, Oriol Dols‐Icardo, Sebastiaan Engelborghs, Bart Buelens, Roosmarijn E. Vandenbroucke, Yannick Vermeiren, Kurt Boonen, Inge Mertens Journal of Extracellular Vesicles.2023;[Epub] CrossRef
The connection between cerebral amyloid angiopathy and Alzheimer’s disease Hans Rolf Jäger European Radiology.2023; 34(4): 2171. CrossRef
Young-onset dementia with Lewy Bodies presenting with apathy and alexithymia Stefania Kaninia, Rosaleen A. McCarthy, Zia Saad, George P Pengas Neurocase.2023; 29(6): 191. CrossRef
Autonomic symptoms are predictive of dementia with Lewy bodies Wenzheng Hu, Shuai Liu, Fei Wang, Han Zhu, Xiaoshan Du, Lingyun Ma, Jinghuan Gan, Hao Wu, Xiaodan Wang, Yong Ji Parkinsonism & Related Disorders.2022; 95: 1. CrossRef
Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship? Daniele Urso, Valentina Gnoni, Marco Filardi, Giancarlo Logroscino Frontiers in Psychiatry.2022;[Epub] CrossRef
Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies Yian Gu, Anton Kociolek, Kayri K. Fernandez, Stephanie A. Cosentino, Carolyn Wei Zhu, Zhezhen Jin, James B. Leverenz, Yaakov B. Stern Neurology.2022;[Epub] CrossRef
Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson’s Disease Using Quantitative Indices of 18F-FP-CIT PET/CT Miju Cheon, Seung Min Kim, Sang-Won Ha, Min Ju Kang, Hea-Eun Yang, Jang Yoo Diagnostics.2022; 12(6): 1402. CrossRef
The promise of amplification assays for accurate early detection of α-synucleinopathies: A review Regina Kurapova, Leonidas Chouliaras, John T. O'Brien Experimental Gerontology.2022; 165: 111842. CrossRef
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder Annette Janzen, David Vadasz, Jan Booij, Markus Luster, Damiano Librizzi, Martin T. Henrich, Lars Timmermann, Mahboubeh Habibi, Elisabeth Sittig, Geert Mayer, Fanni Geibl, Wolfgang Oertel Journal of Parkinson's Disease.2022; 12(6): 1921. CrossRef
Lewy body Dementia: What are the challenges of early and accurate diagnosis? Madelaine B. Rañola Australasian Journal of Neuroscience.2022; 32(1): 40. CrossRef
A Systematic Review and Comparison of Neurocognitive Features of Late-Life Attention-Deficit/Hyperactivity Disorder and Dementia With Lewy Bodies Jennifer L. Prentice, Morgan J. Schaeffer, Alexandra K. Wall, Brandy L. Callahan Journal of Geriatric Psychiatry and Neurology.2021; 34(5): 466. CrossRef
Dementia with Lewy bodies in first-generation immigrants in a European memory clinic Kurt Segers, Florence Benoit, Jean-Marie Meyts, Gérald Glibert, Sophie Levy, Murielle Surquin Acta Neurologica Belgica.2021; 121(1): 219. CrossRef
The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer’s disease by cerebral perfusion SPECT-comparison to CIScore Gaku Honda, Shigeki Nagamachi, Masanari Nonokuma, Koichi Takano, Yasuo Kuwabara, Kengo Yoshimitsu, Hitoshi Iida, Koji Ogomori, Hiroaki Kawasaki, Yoshio Tsuboi Japanese Journal of Radiology.2021; 39(2): 198. CrossRef
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences Dariusz Koziorowski, Monika Figura, Łukasz M. Milanowski, Stanisław Szlufik, Piotr Alster, Natalia Madetko, Andrzej Friedman Cells.2021; 10(3): 656. CrossRef
Advances in computerized MRI‐based biomarkers in Alzheimer’s disease Raymond Wong, Yishan Luo, Vincent Chung-tong Mok, Lin Shi Brain Science Advances.2021; 7(1): 26. CrossRef
Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging Shintaro Saito, Kenichi Nakajima, Lars Edenbrandt, Olof Enqvist, Johannes Ulén, Seigo Kinuya EJNMMI Research.2021;[Epub] CrossRef
A direct comparison of the 2005 and 2017 criteria for dementia with Lewy bodies Kurt Segers, Florence Benoit, Jean‐Marie Meyts, Gerald Glibert, Murielle Surquin Psychogeriatrics.2020; 20(5): 785. CrossRef
Parkinson’s disease (PD) is a neurodegenerative disease with heterogeneous pathological and clinical features. Cognitive dysfunction, a frequent non-motor complication, is a risk factor for poor prognosis and shows inter-individual variation in its progression. Of the clinical studies performed to identify biomarkers of PD progression, the Parkinson’s Progression Markers Initiative (PPMI) study is the largest study that enrolled drug-naïve and very early stage PD patients. The baseline characteristics of the PPMI cohort were recently published. The diagnostic utility of cerebrospinal fluid (CSF) biomarkers, including alpha-synuclein (α-syn), total tau, phosphorylated tau at Thr181, and amyloid β1-42, was not satisfactory. However, the baseline data on CSF biomarkers in the PPMI study suggested that the measurement of the CSF biomarkers enables the prediction of future cognitive decline in PD patients, which was consistent with previous studies. To prove the hypothesis that the interaction between Alzheimer’s pathology and α-syn pathology is important to the progression of cognitive dysfunction in PD, longitudinal observational studies must be followed. In this review, the neuropathological nature of heterogeneous cognitive decline in PD is briefly discussed, followed by a summarized interpretation of baseline CSF biomarkers derived from the data in the PPMI study. The combination of clinical, biochemical, genetic and imaging biomarkers of PD constitutes a feasible strategy to predict the heterogeneous progression of PD.
Citations
Citations to this article as recorded by
Highly sensitive biosensor based on IGZO thin-film transistors for detection of Parkinson's disease Tongzheng Li, Tongying Xu, Zhengyang Yao, Yanan Ding, Guoxia Liu, Fukai Shan Applied Physics Letters.2023;[Epub] CrossRef
Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease Joseph Blommer, Toni Pitcher, Maja Mustapic, Erden Eren, Pamela J Yao, Michael P Vreones, Krishna A Pucha, John Dalrymple-Alford, Reza Shoorangiz, Wassilios G Meissner, Tim Anderson, Dimitrios Kapogiannis Brain.2023; 146(1): 195. CrossRef
Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders John P. Seibyl Journal of Nuclear Medicine.2023; 64(1): 12. CrossRef
REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh Journal of Neurology.2022; 269(9): 4836. CrossRef
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease Thomas Kremer, Kirsten I. Taylor, Juliane Siebourg‐Polster, Thomas Gerken, Andreas Staempfli, Christian Czech, Juergen Dukart, Douglas Galasko, Tatiana Foroud, Lana M. Chahine, Christopher S. Coffey, Tanya Simuni, Daniel Weintraub, John Seibyl, Kathleen L Movement Disorders.2021; 36(8): 1972. CrossRef
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis J. M. Hatcher-Martin, J. L. McKay, A. F. Pybus, B. Sommerfeld, J. C. Howell, F. C. Goldstein, L. Wood, W. T. Hu, S. A. Factor npj Parkinson's Disease.2021;[Epub] CrossRef
Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model Mehmet Ozansoy, Muzaffer Beyza Ozansoy, Burak Yulug, Seyda Cankaya, Ertugrul Kilic, Sule Goktekin, Ulkan Kilic Journal of Clinical Neuroscience.2020; 73: 237. CrossRef
Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology Maja Malmberg, Tarja Malm, Oskar Gustafsson, Andrea Sturchio, Caroline Graff, Alberto J. Espay, Anthony P. Wright, Samir El Andaloussi, Anders Lindén, Kariem Ezzat Frontiers in Neuroscience.2020;[Epub] CrossRef
Why would Parkinson’s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses Jon O. Lauring, Tomohiro Ishizu, Hana H. Kutlikova, Felix Dörflinger, Steven Haugbøl, Helmut Leder, Ron Kupers, Matthew Pelowski Neuroscience & Biobehavioral Reviews.2019; 100: 129. CrossRef
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease Tracy R. Melzer, Megan R. Stark, Ross J. Keenan, Daniel J. Myall, Michael R. MacAskill, Toni L. Pitcher, Leslie Livingston, Sophie Grenfell, Kyla-Louise Horne, Bob N. Young, Maddie J. Pascoe, Mustafa M. Almuqbel, Jian Wang, Steven H. Marsh, David H. Mille Frontiers in Neurology.2019;[Epub] CrossRef
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies Kurt A. Jellinger Journal of Neural Transmission.2018; 125(4): 615. CrossRef
Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study George D. Vavougios, Triantafyllos Doskas, Constantinos Kormas, Karen A. Krogfelt, Sotirios G. Zarogiannis, Leonidas Stefanis Journal of the Neurological Sciences.2018; 387: 103. CrossRef
Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease Nooshin Abbasi, Bahram Mohajer, Sima Abbasi, Payam Hasanabadi, Amirhussein Abdolalizadeh, Reza Rajimehr Movement Disorders.2018; 33(3): 431. CrossRef
Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease Mahsa Dolatshahi, Shayan Pourmirbabaei, Aida Kamalian, Amir Ashraf-Ganjouei, Mehdi Yaseri, Mohammad H. Aarabi Frontiers in Neurology.2018;[Epub] CrossRef
Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study Manuel Delgado‐Alvarado, Rosalía Dacosta‐Aguayo, Irene Navalpotro‐Gómez, Belén Gago, Ana Gorostidi, Haritz Jiménez‐Urbieta, Ana Quiroga‐Varela, Javier Ruiz‐Martínez, Alberto Bergareche, María C. Rodríguez‐Oroz Movement Disorders.2018; 33(11): 1809. CrossRef
Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases Ji-Young Choi, Sujin Kim, Hyo-Bum Kwak, Dong-Ho Park, Jae-Hyoung Park, Jeong-Seon Ryu, Chang-Shin Park, Ju-Hee Kang International Neurourology Journal.2017; 21(2): 83. CrossRef
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum, Jianjun Chang, Jaegwon Chung, Chelsea Caspell-Garcia, Peggy Taylor, Brit Mollenhauer, Michael G. Schlossmacher, Larry Ereshefsky, Mark Yen, Catherine Kopil, Mark Frasier, Kenneth Marek, Vicki S. Journal of Neuroinflammation.2017;[Epub] CrossRef
Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias Julie A Fields Archives of Clinical Neuropsychology.2017; 32(7): 786. CrossRef
Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.
Citations
Citations to this article as recorded by
Aggregation-Induced Emission Luminogens: A New Possibility for Efficient Visualization of RNA in Plants Zheng-Chao Yang, Li-Xiang Zhao, Yu-Qi Sang, Xin Huang, Xuan-Chen Lin, Zhi-Ming Yu Plants.2024; 13(5): 743. CrossRef
Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic
Mechanism and Basis of Potential Antioxidant Therapies Aamir Rasool, Robina Manzoor, Kaleem Ullah, Ramsha Afzal, Asad Ul-Haq, Hadia Imran, Imdad Kaleem, Tanveer Akhtar, Anum Farrukh, Sahir Hameed, Shahid Bashir CNS & Neurological Disorders - Drug Targets.2024; 23(7): 852. CrossRef
Effectiveness of Flavonoid-Rich Diet in Alleviating Symptoms of Neurodegenerative Diseases Aneta Szulc, Karolina Wiśniewska, Magdalena Żabińska, Lidia Gaffke, Maria Szota, Zuzanna Olendzka, Grzegorz Węgrzyn, Karolina Pierzynowska Foods.2024; 13(12): 1931. CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare Acta Neuropathologica.2022; 143(1): 55. CrossRef
Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion Shin Hye Noh, Ye Jin Kim, Min Goo Lee Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593. CrossRef
Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya Immunology.2021; 162(2): 160. CrossRef
Electrogastrography for diagnosis of early-stage Parkinson's disease Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina Parkinsonism & Related Disorders.2021; 86: 61. CrossRef
Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf Molecules.2021; 26(12): 3736. CrossRef
Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim Neurochemical Research.2021; 46(12): 3123. CrossRef
Immunotherapies for Parkinson’s Disease: Progression of Clinical Development Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh CNS & Neurological Disorders - Drug Targets.2021; 20(9): 802. CrossRef
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker Pharmacological Reviews.2021; 73(4): 1204. CrossRef
Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson Frontiers in Immunology.2020;[Epub] CrossRef
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova Translational Neurodegeneration.2020;[Epub] CrossRef
Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine Frontiers in Neuroscience.2020;[Epub] CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll Alzheimer's Research & Therapy.2020;[Epub] CrossRef
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar Molecular Neurobiology.2019; 56(7): 4799. CrossRef
The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies Datis Kharrazian, Martha Herbert, Aristo Vojdani Toxics.2019; 7(2): 26. CrossRef
Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman Alzheimer's & Dementia.2019; 15(9): 1133. CrossRef
Translational therapies for multiple system atrophy: Bottlenecks and future directions Nadia Stefanova Autonomic Neuroscience.2018; 211: 7. CrossRef
Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang Redox Biology.2018; 14: 600. CrossRef
Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus Journal of Neuroimmunology.2018; 315: 33. CrossRef
Beneficial Effects of Flavonoids Against Parkinson's Disease Un Ju Jung, Sang Ryong Kim Journal of Medicinal Food.2018; 21(5): 421. CrossRef
Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases Jiyoon Kim, Heon Yung Gee, Min Goo Lee Journal of Cell Science.2018;[Epub] CrossRef
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova Frontiers in Neuroscience.2018;[Epub] CrossRef
Gene therapy for neurological disorders: progress and prospects Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah Nature Reviews Drug Discovery.2018; 17(9): 641. CrossRef
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies Edward Rockenstein, Gary Ostroff, Fusun Dikengil, Florentina Rus, Michael Mante, Jazmin Florio, Anthony Adame, Ivy Trinh, Changyoun Kim, Cassia Overk, Eliezer Masliah, Robert A. Rissman The Journal of Neuroscience.2018; 38(4): 1000. CrossRef
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace, Journal of Neural Transmission.2017; 124(6): 721. CrossRef
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease Xiaoli Si, Jiali Pu, Baorong Zhang Journal of Movement Disorders.2017; 10(2): 69. CrossRef
Membrane Trafficking Illuminates a Path to Parkinson’s Disease Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki The Tohoku Journal of Experimental Medicine.2017; 242(1): 63. CrossRef
Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus Scientific Reports.2017;[Epub] CrossRef
Impact of aging immune system on neurodegeneration and potential immunotherapies Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao Progress in Neurobiology.2017; 157: 2. CrossRef
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt PLOS ONE.2017; 12(9): e0184731. CrossRef
Vaccination strategies in tauopathies and synucleinopathies Anne K. Braczynski, Jörg B. Schulz, Jan‐Philipp Bach Journal of Neurochemistry.2017; 143(5): 467. CrossRef
Missions of <italic>Journal of Movement Disorders</italic> Yun Joong Kim Journal of Movement Disorders.2016; 9(1): 1. CrossRef
How strong is the evidence that Parkinson's disease is a prion disorder? Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower Current Opinion in Neurology.2016; 29(4): 459. CrossRef